Vivalis, GSK get FDA nod for influenza vaccine trial with EB66 technology
The investigational new drug application is held by GSK. The Vivalis and GSK global collaboration and license agreement aims to develop cell-based manufacturing of seasonal and pandemic human
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.